Roche has obtained a CE mark for its cobas SARS-CoV-2 Qualitative test to identify the virus using saliva samples on the cobas 6800/8800 Systems. The test is indicated for use in asymptomatic people and those who are suspected of Covid-19. The non-invasive test is offered as a self-collect test, where users can obtain saliva samples on-site under the supervision of healthcare specialists. Apart from testing with saliva samples, the test is approved for use with nasal, nasopharyngeal, and oropharyngeal swab specimens to identify infection including those caused by the Omicron variant.

 The Indian Council for Medical Research (ICMR) has granted approval to domestic company GenePath Diagnostics’ CoviDelta kit for the identification of all the current SARS-CoV-2 viral variants. The kit is claimed to detect the Delta and Omicron variants of the virus from a single test. Developed in the country, the rapid and cost-efficient test has sensitivity and specificity of 100%, respectively. Furthermore, the test can also identify the sub-lineages of all the Delta and Omicron variants.

A US town, Barnstable has received 6,000 Covid-19 test kits from the state to potentially test approximately 13,000 individuals, reported. These tests are planned to be supplied to the underprivileged population and those who could not afford to buy covid-19 tests. In this regard, the town has selected more than 100 communities in the Commonwealth with most of them under the poverty level. On delivering the shipment, the kits were supplied to various organisations in Barnstable to facilitate delivery to the lower-income population.